Table 1 Baseline characteristics of IgAN patients
Clinical data | Patients (n = 118) | LVH- (n = 27) | LVH + (n = 91) | p value |
|---|---|---|---|---|
Male/Female (n/%) | 79/39 (67/33) | 13/14 (48/52) | 66/25 (73/27) | 0.039 |
Age (year) | 53.5 ± 13.5 | 49 ± 12.9 | 54.8 ± 13.2 | 0.023 |
Average follow-up time (months) | 184.2 ± 81.9 | 200.7 ± 66.4 | 179.4 ± 85.66 | NS |
24 h average systolic/diastolic blood pressure (Hgmm) | 124/74 ± 13/9 | 117/70 ± 14/9 | 126/75 ± 9/7 | 0.001 |
24 h pulse pressure (Hgmm) | 49.8 ± 9.52 | 47.2 ± 7.01 | 50.5 ± 10.03 | NS |
Diurnal index systolic (%) | 9.54 ± 7.01 | 8.36 ± 5.38 | 9.88 ± 7.40 | NS |
Metabolic parameters | ||||
Hypertension (n, %) | 90 (76) | 14 (52) | 76 (83) | 0.001 |
Dyslipidemia (n, %) | 54 (46) | 9 (33) | 45 (49) | NS |
Obesity (n, %) | 31 (26) | 3 (11) | 28 (31) | NS |
Prediabetes (IFG and IGT) (n, %) | 5 (4) | 1 (4) | 4 (4) | NS |
Diabetes mellitus (n, %) | 30 (25) | 3 (11) | 27 (30) | NS |
eGFR (ml/min) | 85.4 ± 35.8 | 96.7 ± 39.3 | 82.0 ± 34.24 | 0.036 |
Smoking (n, %) | 17 (14) | 0 (0) | 17 (19) | 0.047 |
Metabolic syndrome (n, %) | 27 (23) | 2 (7) | 25 (27) | 0.014 |
Duration of kidney disease (year) | 10.01 ± 9.70 | 9.40 ± 7.47 | 10.2 ± 10.30 | NS |
Echocardiography | ||||
LV EF (%) | 62.69 ± 6.39 | 61.84 ± 6.20 | 62.93 ± 6.46 | NS |
LVMI (g/m2) | 107.34 ± 23.22 | 87.08 ± 16.30 | 113.56 ± 21.51 | 0.012 |
LVM (g) | 207.66 ± 51.95 | 165.25 ± 46.03 | 196.51 ± 46.76 | 0.022 |
LVEDD (cm) | 4.97 ± 0.43 | 4.91 ± 0.47 | 4.99 ± 0.41 | NS |
DD (%) | 55 (47) | 9 (32) | 46 (51) | NS |
E/A | 1.05 ± 0.25 | 1.14 ± 0.29 | 0.93 ± 0.21 | NS |
Ergometry | ||||
Average heart rate (beat/min) | 73.85 ± 13.92 | 75.12 ± 8.79 | 73.75 ± 15.0 | NS |
Stress test time (s) | 575.23 ± 186.73 | 614.66 ± 195.54 | 563.53 ± 183.52 | NS |
CAD (positive stress test) | 16 (14) | 1 (4) | 15 (16) | 0.040 |
Therapy at the start | ||||
ACEI/ARB therapy (n, %) | 100 (85) | 21 (78) | 79 (87) | NS |
BB (n, %) | 31 (26) | 5 (19) | 26 (29) | NS |
Statin (n, %) | 37 (31) | 4 (15) | 33 (36) | 0.027 |
CCB (n, %) | 31 (26) | 5 (19) | 26 (29) | NS |
Laboratory results | ||||
Hb (g/dl) | 13.75 ± 1.66 | 13.93 ± 1.41 | 13.69 ± 1.73 | NS |
MAU (mg/day) | 466.22 ± 639.65 | 387.26 ± 629.39 | 496.89 ± 637.26 | NS |
UA (umol/l) | 321.71 ± 90.57 | 282.59 ± 88.18 | 333.02 ± 88.62 | NS |
Total cholesterol (mmol/l) | 4.95 ± 1.24 | 4.77 ± 0.75 | 5.01 ± 1.35 | NS |
HDL chol (mmol/l) | 1.28 ± 0.46 | 1.30 ± 0.35 | 1.27 ± 0.49 | NS |
TG (mmol/l) | 1.72 ± 1.10 | 1.36 ± 0.66 | 1.83 ± 1.18 | 0.025 |
Endpoints | ||||
Primary combined endpoints (n/%) | 42 (35) | 4 (15) | 35 (42) | 0.028 |
Cardiovascular events (n/%) | 13 (11) | 1 (4) | 12 (13) | 0.045 |
Renal events (n/%) | 29 (24) | 3 (11) | 26 (28) | 0.024 |